Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-0-30-253-8800
Debt
Debt-to-Equity RatioN/A
Current Ratio6.38
Quick Ratio6.38
Price-To-Earnings
Trailing P/E Ratio-4.43
Forward P/E Ratio-7.31
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.36 million
Price / Sales27.99
Cash FlowN/A
Price / CashN/A
Book Value$2.79 per share
Price / Book6.81
Profitability
EPS (Most Recent Fiscal Year)($4.29)
Net Income$-82,610,000.00
Net Margins-178.79%
Return on Equity-67.34%
Return on Assets-23.01%
Miscellaneous
Employees83
Outstanding Shares22,630,000
Market Cap$429.88 million
Merus (NASDAQ:MRUS) Frequently Asked Questions
What is Merus' stock symbol?
Merus trades on the NASDAQ under the ticker symbol "MRUS."
How were Merus' earnings last quarter?
Merus NV (NASDAQ:MRUS) issued its earnings results on Thursday, July, 26th. The biotechnology company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.33. The biotechnology company had revenue of $11.84 million for the quarter, compared to the consensus estimate of $3.47 million. Merus had a negative net margin of 178.79% and a negative return on equity of 67.34%. View Merus' Earnings History.
When is Merus' next earnings date?
What price target have analysts set for MRUS?
3 brokers have issued twelve-month price targets for Merus' shares. Their predictions range from $28.00 to $34.00. On average, they anticipate Merus' stock price to reach $30.6667 in the next year. This suggests a possible upside of 61.4% from the stock's current price. View Analyst Price Targets for Merus.
What is the consensus analysts' recommendation for Merus?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.
Who are some of Merus' key competitors?
Some companies that are related to Merus include Phibro Animal Health (PAHC), Clovis Oncology (CLVS), Nabriva Therapeutics (NBRV), Corcept Therapeutics (CORT), Akorn (AKRX), Insmed (INSM), Theravance Biopharma (TBPH), Aimmune Therapeutics (AIMT), Arrowhead Pharmaceuticals (ARWR), Tricida (TCDA), Wave Life Sciences (WVE), TherapeuticsMD (TXMD), Innoviva (INVA), ARMO Biosciences (ARMO) and Biohaven Pharmaceutical (BHVN).
Who are Merus' key executives?
Merus' management team includes the folowing people:
- Dr. Ton Logtenberg Ph.D., Co-Founder, CEO & Exec. Director (Age 60)
- Dr. Wolfgang Berthold, Consultant (Age 71)
- Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
- Mr. John J. Crowley, CFO & Exec. VP (Age 44)
- Mr. John de Kruif Ph.D., CTO & Sr. VP
When did Merus IPO?
(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Who are Merus' major shareholders?
Merus' stock is owned by a number of of institutional and retail investors. Top institutional investors include Aquilo Capital Management LLC (5.53%), Stanley Laman Group Ltd. (0.25%), Renaissance Technologies LLC (0.21%), DRW Securities LLC (0.06%) and California Public Employees Retirement System (0.04%).
Which major investors are buying Merus stock?
MRUS stock was purchased by a variety of institutional investors in the last quarter, including Aquilo Capital Management LLC, DRW Securities LLC, Stanley Laman Group Ltd., Renaissance Technologies LLC and California Public Employees Retirement System.
How do I buy shares of Merus?
Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merus' stock price today?
One share of MRUS stock can currently be purchased for approximately $19.00.
How big of a company is Merus?
Merus has a market capitalization of $429.88 million and generates $15.36 million in revenue each year. The biotechnology company earns $-82,610,000.00 in net income (profit) each year or ($4.29) on an earnings per share basis. Merus employs 83 workers across the globe.
What is Merus' official website?
How can I contact Merus?
Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]
MarketBeat Community Rating for Merus (NASDAQ MRUS)
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
